Bolder BioTechnology wins $1.6 million NIH grant
George Cox, president of Bolder BioTechnology, said: “We are grateful to receive continued support from the National Institute of Neurological Disorders and Stroke (NINDS) for our long-acting beta
Swedish Orphan Biovitrum (Sobi) has received a complete response letter from the US Food and Drug Administration (FDA) regarding its biologics licence application for nanoencapsulated sirolimus plus pegadricase (NASP), an investigational therapy intended for adults with uncontrolled gout.